Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 9/20 | 0.79 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.72 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.72 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.72 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.72 |
| ▸ | CASP7 | P55210 | 3/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5084428 | 1.00 | GPBAR1 (0.79) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| SCHEMBL1656467 | 1.00 | GPBAR1 (0.79) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| SCHEMBL22717115 | 1.00 | GPBAR1 (0.79) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| Ursulcholic Acid SCHEMBL5683101 | 0.92 | GPBAR1 (0.72) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| Ursulcholic Acid SCHEMBL27095060 | 0.91 | ABCC4 (0.77) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| Ursulcholic Acid SCHEMBL2919469 | 0.91 | ABCC4 (0.77) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| Ursulcholic Acid SCHEMBL6269998 | 0.91 | ABCC4 (0.77) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| SCHEMBL24208313 | 0.90 | GPBAR1 (0.75) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| SCHEMBL22079151 | 0.90 | GPBAR1 (0.75) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| SCHEMBL21710942 | 0.90 | GPBAR1 (0.72) | GPBAR1NR1H4TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016138-A1 | SYNTHETIC DERIVATIVES OF CHOLIC ACID 7-SULFATE AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-01-20 | — | — | US | claimed |
| EP-3890745-A1 | SYNTHETIC DERIVATIVES OF CHOLIC ACID 7-SULFATE AND USES THEREOF | President and Fellows of Harvard College (US) | 2021-10-13 | — | — | EP | claimed |
| WO-2020117945-A1 | SYNTHETIC DERIVATIVES OF CHOLIC ACID 7-SULFATE AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-11 | — | — | WO | claimed |
| US-9724357-B2 | Methods for preserving photoreceptor cell viability following retinal detachment | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160051567-A1 | PREVENTION AND TREATMENT OF KIDNEY DAMAGE | METSELEX, INC. (US) | 2016-02-25 | — | — | US | disclosed |
| US-20150072967-A1 | TAUROURSODEOXYCHOLIC ACID ATTENTUATES OR ABOLISHES FORMATION AND DEPOSITION OF AMYLOID-B PEPTIDE | METSELEX, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140323455-A1 | METHODS FOR PRESERVING PHOTORECEPTOR CELL VIABILITY FOLLOWING RETINAL DETACHMENT | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2014-10-30 | — | — | US | disclosed |
| WO-2014160877-A1 | PREVENTION AND TREATMENT OF KIDNEY DAMAGE BY BILE ACIDS | METSELEX, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2013142490-A2 | TAUROURSODEOXYCHOLIC ACID ATTENUATES OR ABOLISHES FORMATION AND DEPOSITION OF AMYLOID-B PEPTIDE | METSELEX, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013025840-A1 | METHODS FOR PRESERVING PHOTORECEPTOR CELL VIABILITY FOLLOWING RETINAL DETACHMENT | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2013-02-21 | — | — | WO | disclosed |
| EP-0871452-B1 | SULFATE CONJUGATES OF URSODEOXYCHOLIC ACID, AND THEIR BENEFICIAL USE IN INFLAMMATORY DISORDERS AND OTHER APPLICATIONS | CHILDRENS HOSP MEDICAL CENTER (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20060204481-A1 | Methods of promoting cell viability | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-09-14 | — | — | US | disclosed |
| EP-1615497-A2 | METHODS OF PROMOTING CELL VIABILITY | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004096123-A2 | METHODS OF PROMOTING CELL VIABILITY | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004012686-A2 | NITROSATED AND/OR NITROSYLATED URSODEOXYCHOLIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-6251884-B1 | PHARMACOLOGICALLY ACCEPTABLE COMPOSITION FOR INHIBITING OR TREATING LIVER DISEASE OR INFLAMMATORY CONDITION OF GASTROINTESTINAL TRACT IN MAMMAL, COMPRISING SULFATE OF URSODEOXYCHOLIC ACID OR SALT THEREOF, CARRIER | CHILDREN'S HOSPITAL MEDICAL CENTER | 2001-06-26 | — | — | US | disclosed |
| EP-0871452-A2 | SULFATE CONJUGATES OF URSODEOXYCHOLIC ACID, AND THEIR BENEFICIAL USE IN INFLAMMATORY DISORDERS AND OTHER APPLICATIONS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5763435-A | ADMINISTERING TO MAMMAL TO TREAT LIVER DISEASE OR INFLAMMATORY CONDITION OF GASTROINTESTINAL TRACT | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1997018816-A9 | SULFATE CONJUGATES OF URSODEOXYCHOLIC ACID, AND THEIR BENEFICIAL USE IN INFLAMMATORY DISORDERS AND OTHER APPLICATIONS | — | 1997-10-09 | — | — | WO | disclosed |
| WO-1997018816-A2 | SULFATE CONJUGATES OF URSODEOXYCHOLIC ACID, AND THEIR BENEFICIAL USE IN INFLAMMATORY DISORDERS AND OTHER APPLICATIONS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016138-A1 | SYNTHETIC DERIVATIVES OF CHOLIC ACID 7-SULFATE AND USES THEREOF | CYP7A1, NR1H4, CYP7B1 | GPBAR1 31/4885NR1H4 2/4885TDP1 3877/4885 |
| US-20140323455-A1 | METHODS FOR PRESERVING PHOTORECEPTOR CELL VIABILITY FOLLOWING RETINAL DETACHMENT | ALDH1A2, CRYAA, UACA | GPBAR1 22/4885NR1H4 6/4885TDP1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.